Since the first case of COVID-19, the whole world has been waiting for good news. Only last month, manufacturers of vaccines have given some very welcome news. Well-designed large clinical trials of vaccine candidates have shown promise, with some exceeding 90% efficacy and equally importantly, none reporting worrying safety signals. Despite these findings, some scientific and logistics questions remain unanswered.

Based on the above scenario, this essay addressing the COVID-19 vaccine distribution challenge for India.